LinkedIn co-founder Reid Hoffman is stepping away from one of Big Tech’s most influential boardrooms just as artificial intelligence reshapes both software and drug discovery.
Early role and rise inside Microsoft
Hoffman joined Microsoft’s board after the tech giant acquired LinkedIn for $26.2 billion, formally taking a director seat in 2017.1 His tenure coincided with Microsoft’s aggressive push into AI, including its landmark $1 billion investment in OpenAI in 2019, a move widely seen as reshaping the company’s strategic direction.2
During these years, Hoffman was not only a Microsoft director but also deeply embedded in the broader AI ecosystem. He had been an early OpenAI investor and later sat on its board until 2023, when he stepped down citing mounting conflicts of interest as his AI activities expanded.2
Growing conflicts and the Inflection deal
Those conflicts intensified when Microsoft struck a $650 million “acqui-hire” deal with Inflection AI, the startup Hoffman co-founded, bringing co-founder Mustafa Suleyman into Microsoft to lead a superintelligence-focused AI division.2 The transaction raised fresh regulatory questions about how deeply intertwined Big Tech boards and AI startups could become.
Decision to leave and shift to ‘founder mode’
By early June 2026, Microsoft disclosed in a regulatory filing that Hoffman would not stand for reelection and would leave the board at the next shareholder meeting.12 Public reports framed the move simply: “LinkedIn co-founder Reid Hoffman is leaving Microsoft’s board.”1
Hoffman has cast the decision as a return to hands-on entrepreneurship with Manus, his AI-powered drug discovery startup. He says he wants to go “founder mode” with Manus,2 which has raised over $50 million across two seed rounds and is led by oncologist and author Dr. Siddhartha Mukherjee.2 Manus is pursuing what Hoffman calls “Move 37” AI—systems that can surpass human creativity in fields like chemistry to discover new cancer-fighting compounds.2
As Big Tech’s AI bets collide with fast-growing biotech ambitions, Hoffman’s exit underscores how boardroom influence, startup leadership, and regulatory scrutiny are becoming harder to separate.